BrainXell, Inc. presented data during poster sessions at the 2025 Society for Neuroscience (SfN) Annual Meeting in San Diego this month, highlighting new breakthroughs in human iPSC-derived cell models and regenerative neuroscience.
These presentations underscore BrainXell’s focus on scientific discovery and clinical translation, spanning scalable cell-based assays, advanced disease modelling, and next-generation cell therapies for neurodegenerative disorders.
Dr Su-Chun Zhang, BrainXell Founder and Advising CSO, states, “BrainXell is at the forefront of the biotechnology industry, engineering novel cellular platforms for biomedical discovery and pharmaceutical development, as well as developing personalised regenerative therapy for devastating neurological diseases.”
At the center, BrainXell Therapeutic presented data for BXT-110, an autologous iPSC-derived midbrain dopaminergic progenitor (mDAP) therapy for Parkinson’s disease. The data demonstrates more than 75% FOXA2+/OTX2+ expression, over 60% TH+ neurons in vitro and greater than 60% graft survival in vivo. Functional efficacy in rodent model, demonstrated by a significant behavioural recovery within 12 weeks post transplantation with BXT-110, supporting BXT-110 as a robust candidate for disease-modifying therapy.
Complementing this translational work, BrainXell scientists have also engineered a 3D neurovascular microfluidic model of the human blood–brain barrier. The tri-culture system of endothelial cells, astrocytes, and pericytes accurately replicates barrier integrity and permeability, providing a quantitative platform for CNS drug transport and safety studies.
Another study details an accelerated differentiation protocol for hiPSC-derived oligodendrocyte progenitor cells, reaching more than 95% O4⁺ purity and expressing key myelin markers (MBP, MOG, PLP1) within 30 days. Integrated into 3D co-cultures, these cells exhibited enhanced arborisation and myelination, offering new tools for remyelination research.
Finally, BrainXell’s development of multilineage 3D neural spheroids integrating neurons, astrocytes, and microglia demonstrated coordinated network activity, synaptic signalling, and neuroinflammatory responses—advancing physiologically relevant models that bridge in vitro assays and in vivo biology.
#pharmapress
#drugdiscovery
#drugdevelopment
#drugdiscoveryanddevelopment
